Drug · CHEMBL3545367
LEMBOREXANT
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LEMBOREXANT. Drugs and targets, record CHEMBL3545367. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545367
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HCRTR1 | Orexin/Hypocretin receptor type 1 | Orexin receptor 1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/3061 |
| HCRTR2 | Orexin receptor type 2 | Orexin receptor 2 antagonist | ANTAGONIST | https://conductscience.org/library/genes/3062 |
Source ChEMBL
Diseases13
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 13Source Open Targets
See all 13 diseasesTrials52
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02783729 | Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) | Phase 3 | 1,006 | 2020-02-11 | lemborexant | Its name | ClinicalTrials.gov |
| NCT02952820 | Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2) | Phase 3 | 971 | 2020-01-21 | lemborexant | Its name | ClinicalTrials.gov |
| NCT01995838 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia | Phase 2 | 291 | 2020-01-31 | lemborexant | Its name | ClinicalTrials.gov |
| NCT04549168 | A Study of Lemborexant in Chinese Participants With Insomnia Disorder | Phase 3 | 194 | 2024-12-20 | lemborexant | Its name | ClinicalTrials.gov |
| NCT03471871 | Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea | Phase 1 | 146 | 2020-01-18 | lemborexant | Its name | ClinicalTrials.gov |
| NCT01463098 | A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 | Phase 1 | 122 | 2020-01-18 | E2006 | Its name | ClinicalTrials.gov |
| NCT02350309 | Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder | Phase 1 | 69 | 2020-01-18 | lemborexant | Its name | ClinicalTrials.gov |
| NCT05594589 | A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder | Phase 2 | 65 | 2025-07-03 | lemborexant | Its name | ClinicalTrials.gov |
| NCT03001557 | Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | Phase 2 | 63 | 2020-01-14 | lemborexant | Its name | ClinicalTrials.gov |
| NCT04647383 | A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 1 | 63 | 2023-10-10 | lemborexant | Its name | ClinicalTrials.gov |
1 to 10 of 52
See all 52 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Active Treatment vs Placebo Treatment: deaths from any cause | 0 of 15 | 0 of 14 | 29 | NCT05344443 | Trial comparisons |
| Active Treatment vs Placebo Treatment: serious adverse events | 0 of 15 | 0 of 14 | 29 | NCT05344443 | Trial comparisons |
| Lemborexant Arm vs Placebo Arm: deaths from any cause | 0 of 12 | 0 of 6 | 18 | NCT04818086 | Trial comparisons |
| Lemborexant Arm vs Placebo Arm: serious adverse events | 0 of 12 | 0 of 6 | 18 | NCT04818086 | Trial comparisons |
| Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Parameter Values | 0 of 8 | 0 of 8 | 16 | NCT03443063 | Trial comparisons |
| Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: Number of Participants With Clinically Significant Abnormal Vital Sign Values | 0 of 8 | 0 of 8 | 16 | NCT03443063 | Trial comparisons |
| Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: Number of Participants With Clinically Significant Laboratory Abnormalities | 0 of 8 | 0 of 8 | 16 | NCT03443063 | Trial comparisons |
| Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: deaths from any cause | 0 of 8 | 0 of 8 | 16 | NCT03443063 | Trial comparisons |
| Lemborexant: Severe Renal Impairment vs Lemborexant: Normal Renal Function: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT03443063 | Trial comparisons |
Papers from its trials36
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 35112665 | RESULT | 1 | PubMed |
| 42844407 | DERIVED | 1 | PubMed |
| 42414855 | DERIVED | 1 | PubMed |
| 42226892 | DERIVED | 1 | PubMed |
| 41938624 | DERIVED | 2 | PubMed |
| 41442783 | DERIVED | 1 | PubMed |
| 41151943 | DERIVED | 1 | PubMed |
| 41103818 | DERIVED | 1 | PubMed |
| 40848323 | DERIVED | 2 | PubMed |
| 40346496 | DERIVED | 1 | PubMed |
1 to 10 of 36
See all 36 papers from its trialsTests in its trials7
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Choice Reaction Time | 3 | 1 | ConductCognition |
| Delay Discounting | 2 | 1 | ConductCognition |
| Delayed Recall Module | 2 | 1 | ConductCognition |
| Psychomotor Vigilance Task | 2 | 1 | ConductCognition |
| Simple Reaction Time | 2 | 1 | ConductCognition |
| Symbol Coding | 2 | 1 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL3545367
GET https://conductscience.org/api/drugs/v1/CHEMBL3545367/trials?page=2